A
Arturo Cesaro
Researcher at Seconda Università degli Studi di Napoli
Publications - 93
Citations - 1057
Arturo Cesaro is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 49 publications receiving 437 citations. Previous affiliations of Arturo Cesaro include Leonardo.
Papers
More filters
Journal ArticleDOI
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy
Felice Gragnano,Simona Sperlongano,Enrica Golia,Francesco Natale,Renatomaria Bianchi,Mario Crisci,Fabio Fimiani,Ivana Pariggiano,Vincenzo Diana,Andreina Carbone,Arturo Cesaro,Claudia Concilio,Giuseppe Limongelli,Mariagiovanna Russo,Paolo Calabrò +14 more
TL;DR: Results from animal models and clinical studies support the potent anti-inflammatory and antithrombotic effect of VWF antagonism, providing reassuring data on its safety profile, and provides an updated overview of the drugs that can directly interfere with the VWF/ADAMTS13 axis.
Journal ArticleDOI
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry
Pasquale Paolisso,Luca Bergamaschi,Gaetano Santulli,Emanuele Gallinoro,Arturo Cesaro,Felice Gragnano,Celestino Sardu,Niya Mileva,Alberto Foà,Matteo Armillotta,Angelo Sansonetti,S. Amicone,A. Impellizzeri,Gianni Casella,Ciro Mauro,Dobrin Vassilev,Raffaele Marfella,Paolo Calabrò,Emanuele Barbato,Carmine Pizzi +19 more
TL;DR: In this paper , the authors investigated the link between stress hyperglycemia, inflammatory burden, and infarct size in a cohort of type 2 diabetic patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic (OAD) agents.
Journal ArticleDOI
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies.
Arturo Cesaro,Alessandra Schiavo,Elisabetta Moscarella,Silvio Coletta,Matteo Conte,Felice Gragnano,Fabio Fimiani,Emanuele Monda,Martina Caiazza,Giuseppe Limongelli,Laura D'Erasmo,Carmine Riccio,Marcello Arca,Paolo Calabrò +13 more
TL;DR: An updated overview of current evidence on Lp(a) as well as currently investigated therapeutic strategies that specifically address the reduction of the lipoprotein are provided.
Journal ArticleDOI
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.
Arturo Cesaro,Vanessa Bianconi,Felice Gragnano,Elisabetta Moscarella,Fabio Fimiani,Emanuele Monda,Olga Scudiero,Giuseppe Limongelli,Matteo Pirro,Paolo Calabrò +9 more
TL;DR: This review provides a comprehensive overview of the genetics, biochemical structure, expression, and function of PCSK9 and discusses the potential implications of its long‐term pharmacological inhibition.
Journal ArticleDOI
Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease.
Felice Gragnano,Fabio Fimiani,Marco Di Maio,Arturo Cesaro,Giuseppe Limongelli,Davide Cattano,Paolo Calabrò +6 more
TL;DR: The impact of Lp(a) levels on the recurrence of cardiovascular events in patients with premature CAD treated with percutaneous coronary intervention (PCI) is assessed.